Research guide · BPC-157 / TB-500
BPC-157 and TB-500: what they are and where the research stands
Last updated: 27 August 2026
BPC-157 and TB-500 are two peptides frequently paired in tissue-repair research. The literature on each is developing, and the way they are described commercially often overstates what has been established.
This page covers what each is, how each is described in the research literature, where that research currently stands, and what to check before buying. It does not contain usage or dosing guidance.
Research use only · 18+What they are
Two peptides commonly studied together
BPC-157
Sequence: a 15-amino-acid synthetic peptide.
Origin: derived from a partial sequence of a protein found in human gastric juice, referred to in the literature as “body protection compound.”
Research context: studied in preclinical models for its effects on tendon, ligament, muscle and gastrointestinal tissue.
TB-500
Sequence: a synthetic peptide fragment based on a portion of the thymosin beta-4 (Tβ4) molecule, which is naturally present in most mammalian cell types.
Research context: studied in preclinical models for its role in actin regulation, cell migration and angiogenesis.
The two are often supplied together commercially because researchers frequently investigate them alongside each other. That is a commercial pairing, not evidence that combined administration is more effective in any regulated sense.
Regulatory status
Where the research stands
Both BPC-157 and TB-500 are investigational. Neither has been authorised for medical use by the MHRA in the United Kingdom, by the EMA in Europe, or by the FDA in the United States.
That means:
- Neither is a licensed medicine in the UK.
- Neither can lawfully be sold or supplied for human use here.
- Anything offered for sale is supplied for laboratory research purposes only.
- Neither has completed the full regulatory review that licensed medicines undergo.
The FDA has explicitly excluded BPC-157 from the categories of substances that compounding pharmacies may prepare, citing insufficient safety data for human use. TB-500 has been referenced separately in anti-doping regulations by WADA, which lists thymosin beta-4 among prohibited substances in competitive sport.
Any seller presenting either compound as an approved therapy or a licensed product is misrepresenting it.
The research literature
What has, and has not, been established
The published literature for both peptides is dominated by preclinical work: cell culture experiments and animal studies, primarily in rats and mice. This is the standard starting point for early-stage biological research.
What that literature describes:
- Effects observed in vitro (in isolated cells) or in vivo (in laboratory animals).
- Mechanistic pathways proposed based on those observations.
- Model systems for further research.
What that literature does not establish:
- Safe or effective use in humans.
- Dosing schedules for humans.
- Long-term safety.
- Comparative effectiveness against approved treatments.
Human clinical trial evidence for either compound remains very limited. Sellers commonly present preclinical findings as if they were human clinical outcomes. That is a misrepresentation of the underlying research.
What the research shows
Selected findings from the published literature
The BPC-157 and TB-500 literature spans several decades of preclinical work and, more recently, early-phase human studies. The findings below are drawn from peer-reviewed publications and are reported as observed in the referenced study — they do not describe therapeutic use in humans.
BPC-157
2006Preclinical · rat
Achilles tendon-to-bone healing after sharp transection
In this model, tendon-to-bone healing did not occur spontaneously in controls but was recovered in animals receiving BPC-157. Load to failure, stiffness and elasticity modulus all increased significantly, with parallel improvements in collagen organisation and vascular appearance.
Krivic A et al. J Orthop Res. 2006. PMID: 16583442. DOI: 10.1002/jor.20096.
2004Preclinical · rat
Gastric ulcer models: indomethacin, pylorus-ligation, and acetate
BPC-157 produced dose-dependent reductions in ulcer area across all three models. In the indomethacin model, intramuscular administration produced ulcer-area inhibition of 53.5%, 65.5% and 65.5% at 200, 400 and 800 ng/kg respectively. Comparable dose-dependent effects were observed in the pylorus-ligation and acetate models.
Xue XC et al. World J Gastroenterol. 2004. PMCID: PMC4717094. DOI: 10.3748/wjg.v10.i7.1032.
2021Preclinical review · multi-model
Wound healing across multiple tissue types
The review summarises effects observed on incisional and excisional wounds, deep burns, diabetic ulcers, alkali burns, fistulas, and injuries to muscle, tendon, ligament, bone, nerve, liver, and cornea. In one cited experiment, epithelial corneal defects in rats healed within 3–4 days with topical BPC-157 at 2 µg or 2 ng regimens.
Seiwerth S et al. Front Pharmacol. 2021. DOI: 10.3389/fphar.2021.627533.
2021Human · retrospective clinical
Intra-articular injection for knee pain
14 of 16 patients (87.5%) reported significant pain relief. No adverse effects were reported in the follow-up period.
Lee E, Padgett B. Altern Ther Health Med. 2021;27. Note: retrospective, small sample, no control group.
TB-500 (thymosin β4)
2012Preclinical + Phase 2
Dermal wound healing in animals and human ulcer patients
TB-4 accelerated dermal healing across all preclinical animal models. In the Phase 2 clinical trials, TB-4 accelerated healing by approximately one month among patients whose ulcers healed. The authors describe TB-4 as promoting cell migration and stem-cell mobilisation and differentiation.
Treadwell T et al. Ann N Y Acad Sci. 2012;1270:37–44. PMID: 23050815. DOI: 10.1111/j.1749-6632.2012.06717.x.
2018Preclinical + Phase 2 context
RGN-259 (topical TB-4) in a murine dry-eye model
Compared with vehicle and prescription dry-eye comparators, RGN-259 produced 60.3% reduction in corneal irregularity, 51.8% reduction in fluorescein staining, 93.8% reduction in epithelial detachment, and a 2.4-fold increase in goblet cell density at the higher dosing frequency. The paper notes that in a separate Phase 2 trial of topical 0.1% RGN-259, dry-eye signs and symptoms improved with no observed side effects.
Kim CE et al. Sci Rep. 2018;8:10500. DOI: 10.1038/s41598-018-28861-5.
2010–2021Phase 1 · human volunteers
Safety and pharmacokinetics of thymosin β4
Both studies reported that thymosin β4 was well tolerated with no dose-limiting toxicities and no serious adverse events. Terminal clearance was consistent across dose groups and no accumulation occurred after continuous administration.
Ruff D et al. Ann N Y Acad Sci. 2010. DOI: 10.1111/j.1749-6632.2010.05474.x. Wang X et al. J Cell Mol Med. 2021. DOI: 10.1111/jcmm.16693.
All findings above are from published, peer-reviewed sources. None establish safe or effective human use of BPC-157 or TB-500 outside a clinical-trial setting, and neither compound is licensed for human use in the UK, EU or US. Sellers who present these findings as evidence of routine therapeutic use are misrepresenting the underlying research.
Stability
Why format matters
Like all peptides, BPC-157 and TB-500 are chemically fragile once dissolved. Hydrolysis and oxidation begin as soon as the peptide enters solution, and continue for as long as it stays that way.
Pre-filled peptide pens are dissolved at the point of manufacture and remain in solution through shipping, customs clearance, warehousing and delivery to the buyer.
A freeze-dried presentation avoids that. The peptide stays dry and stable until the buyer reconstitutes it.
We cover the format question in full on freeze-dried vs pre-filled.
Frequently asked
Common questions about BPC-157 and TB-500
What is BPC-157?
BPC-157 is a synthetic 15-amino-acid peptide derived from a partial sequence of a protein found in human gastric juice. The name comes from “body protection compound.” It has been studied extensively in preclinical models — cell culture, rats, mice, and small-type pigs — for its effects on tendon, ligament, muscle, and gastrointestinal tissue. It is not a licensed medicine anywhere and remains investigational.
What is TB-500?
TB-500 is a synthetic peptide fragment based on a portion of thymosin beta-4 (Tβ4), a molecule naturally present in most mammalian cell types. In the research literature it has been studied for its effects on actin regulation, cell migration, angiogenesis, and tissue repair. Like BPC-157, it is investigational and not approved for medical use.
Why are BPC-157 and TB-500 sold together?
The two peptides are commonly investigated alongside each other in preclinical tissue-repair research, so many suppliers offer them as a paired kit. This is a commercial convention reflecting research-community usage patterns — not evidence that combined administration is more effective in any regulated sense. Each peptide should be considered on its own merits.
What has BPC-157 research shown?
Peer-reviewed preclinical work includes Krivic et al. (J Orthop Res 2006, PMID 16583442) reporting recovered Achilles tendon-to-bone healing in Wistar rats; Xue et al. (World J Gastroenterol 2004, PMC PMC4717094) reporting dose-dependent ulcer-area reductions of 53.5–65.5% in three gastric ulcer models; and Seiwerth et al. (Front Pharmacol 2021) reviewing effects across multiple tissue types. A 2021 retrospective clinical case series (Lee & Padgett, Altern Ther Health Med) reported symptom improvement in 14 of 16 patients receiving intra-articular injection for knee pain. All findings are described as observed in the referenced study and do not establish approved therapeutic use.
What has TB-500 research shown?
Treadwell et al. (Ann N Y Acad Sci 2012, PMID 23050815) reported accelerated dermal healing in animal models and approximately one month faster healing in two Phase 2 human ulcer trials. Kim et al. (Sci Rep 2018) reported 60–94% reductions in corneal irregularity, fluorescein staining, and epithelial detachment in a murine dry-eye model treated with RGN-259 (topical TB-4). Phase 1 studies in healthy volunteers (Ruff et al., 2010; Wang et al., 2021) reported no serious adverse events and no dose-limiting toxicities.
Are BPC-157 and TB-500 legal in the UK?
Neither compound is authorised as a medicine by the MHRA in the UK, the EMA in the EU, or the FDA in the US. Neither can lawfully be sold for human use. Both may be lawfully supplied for laboratory research purposes only. The FDA has explicitly excluded BPC-157 from the categories of substances that compounding pharmacies may prepare, citing insufficient human safety data. Any seller presenting either compound as an approved medicine is misrepresenting it.
Are BPC-157 or TB-500 banned in competitive sport?
The World Anti-Doping Agency (WADA) Prohibited List includes thymosin beta-4 among substances prohibited in competitive sport, which brings TB-500 (a synthetic Tβ4 fragment) squarely within scope. BPC-157 has been referenced by WADA authorities as falling under the “non-approved substances” category (S0). Athletes considering research compounds must verify their national anti-doping rules directly.
Why does the format of the pen matter?
Peptides are chemically fragile once in solution. Hydrolysis and oxidation begin the moment the compound is dissolved and continue for as long as it stays that way. Pre-filled peptide pens are dissolved at the point of manufacture and remain in solution through shipping, customs, warehousing, and delivery. Freeze-dried format keeps the peptide dry and stable until the buyer reconstitutes it. Full technical detail on freeze-dried vs pre-filled.
What should a research-grade BPC-157 or TB-500 COA show?
Three essentials: purity by HPLC of 98% or higher, identity confirmed by mass spectrometry, and testing by a named independent laboratory with no commercial interest in the result. The COA should reference a specific batch number that matches the product being purchased. See how to read a peptide Certificate of Analysis for the full breakdown.
Where can I find the primary research?
Key BPC-157 papers: Krivic et al. 2006 (Achilles tendon), Xue et al. 2004 (gastric ulcers), Seiwerth et al. 2021 (review, Front Pharmacol). Key TB-500 papers: Treadwell et al. 2012 (dermal wounds, Phase 2), Kim et al. 2018 (RGN-259 dry eye, Sci Rep). All are freely accessible via PubMed or PubMed Central.
Buying checklist
What to check before buying
- Format. Freeze-dried or pre-filled? Pre-filled has been in solution since the factory.
- A published, batch-specific COA from a named independent laboratory. See how to read one.
- Purity by HPLC. 98%+ is the benchmark. Identity by mass spectrometry.
- Honest framing. A seller making therapeutic claims about an unlicensed compound is telling you something about how they operate.
- Storage and shipping conditions. How is the material handled from the lab to your door?
- Batch traceability. Can you match what you received to a specific test result?
Misconceptions
Common misconceptions
“BPC-157 is a natural substance so it must be safe.”The 15-amino-acid research peptide is a synthetic fragment derived from a naturally occurring protein — it is not the same molecule found in the body. Safety in humans has not been established through regulated clinical trials.
“There are hundreds of studies proving it works.”There are hundreds of studies exploring its biological activity in cell culture and animal models. That is different from evidence of safe and effective human use.
“Athletes use it, so it must be effective.”Off-label and unregulated use is not evidence of clinical effectiveness. TB-500 in particular is prohibited in competitive sport by WADA.
“A COA on the website covers everything.”Only if it is batch-specific, recent, independent, and matches the product you are buying.
Our BPC-157 / TB-500
Freeze-dried, tested, batch-traceable
Supplied freeze-dried, not pre-filled, with a bacteriostatic water pen in the same kit. Independently tested by third-party laboratory, with the Certificate of Analysis published per batch in our COA Library.
Supplied strictly for research use.
Research use only. BPC-157 and TB-500 are investigational compounds and are not licensed for human use in the United Kingdom, the European Union or the United States. Supplied strictly for laboratory research purposes. Not for human consumption. Not intended to diagnose, treat, cure or prevent any disease. Purchasers must be 18 or over.